The Institute for Clinical and Economic Review on Thursday released a final evidence report and report-at-a-glance on cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
ICER’s analysis on three cystic fibrosis therapies, Symdeko, Orkambi and Kalydeco, were reviewed during a meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC).
Council members voted that despite the therapies’ benefits, the high price of the drugs produce low long-term value for money. ICER’s report suggests discounts of some 77 percent to align the drugs’ prices with their clinical value.
“Discussions at our meeting highlighted that, while these therapies offer important benefits for those living with CF, the $300,000 annual price is far too high to pay year after year, harming patients and families today while threatening the health care system’s ability to maintain access to important future clinical advances,” ICER CSO Dan Ollendorf said in a statement.
To read ICER’s press release on the report, click here.